Authors’ reply to Ninan and Millar and Abou-salehBMJ 2016; 353 doi: https://doi.org/10.1136/bmj.i2253 (Published 26 April 2016) Cite this as: BMJ 2016;353:i2253
- Kevin M O’Shaughnessy, consultant, reader in clinical pharmacology1,
- Lucinda Kennard, specialist registrar in clinical pharmacology1
- 1Division of Experimental Medicine and Immunotherapeutics, Department of Medicine, University of Cambridge, Addenbrooke’s Hospital, Cambridge CB2 2QQ, UK
Ninan highlights the importance of frailty in the context of treatment for hypertension.1 2 We did not intend to give the impression that “one size fits all.” We agree that an individualised approach is needed in all cases, with a balance being struck between the need to reduce cardiovascular risk versus the risk, for example, of falls from postural hypotension.
With respect to evidence for treatment of hypertension in the frail elderly, we highlight the following:
The HYVET study found lower cardiovascular mortality …